GlassScriptPhysician profile
Ruben J Gil
NPI 1760411003
$9,392.61
in general payments reported to CMS, 2019-2025
24 companies · $714 in 2025
The $714 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $896 · 2020: $1,195 · 2021: $2,255 · 2022: $1,716 · 2023: $1,450 · 2024: $1,165 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,329.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,849.30 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $1,265.44 | 2020-2024 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $875.76 | 2022-2024 | Farxiga |
| Abbott Laboratories | $733.91 | 2020-2025 | Navitor, Coroflow, Assurity |
| Novartis Pharmaceuticals Corporation | $670.42 | 2019-2025 | |
| Amarin Pharma, INC. | $516.62 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $384.83 | 2020-2024 | Xarelto |
| Boston Scientific Corporation | $345.22 | 2024-2025 | Avvigo Guidance System, Watchman Flx, Watchman Access System |
| Heartflow, INC. | $297.72 | 2023-2025 | Ffrct |
| Merck Sharp & Dohme LLC | $257.44 | 2021-2025 | Verquvo |
| Lantheus Medical Imaging, INC. | $250.10 | 2021-2022 | |
| Astellas Pharma US INC | $219.29 | 2022 | |
| Atricure, INC. | $165.81 | 2023 | |
| Sanofi-Aventis U.S. LLC | $143.94 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $136.56 | 2023-2024 | Inpefa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $49.82 | 2025 | Camzyos |
| Regeneron Healthcare Solutions, INC. | $40.00 | 2019 | |
| Pfizer INC. | $37.76 | 2023 | |
| Baxter Healthcare | $37.43 | 2023 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Arbor Pharmaceuticals, INC. | $28.42 | 2021 | |
| Novo Nordisk INC | $27.93 | 2025 | Wegovy |
| Biotronik INC. | $26.13 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.17 | 2025 | |
| Genzyme Corporation | $13.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruben Gil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.